Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Julien Andreani\textsuperscript{a,b}, Marion Le Bideau\textsuperscript{a,b}, Isabelle Duflot\textsuperscript{a,b}, Priscilla Jardot\textsuperscript{a,b}, Clara Rolland\textsuperscript{a,b}, Manon Boxberger\textsuperscript{a,b}, Nathalie Wurtz\textsuperscript{a,b}, Jean-Marc Rolain\textsuperscript{a,b}, Philippe Colson\textsuperscript{a,b}, Bernard La Scola\textsuperscript{a,b,∗∗}, Didier Raoult\textsuperscript{a,b,∗}

\textsuperscript{a} IHU-Méditerranée Infection, Marseille, France
\textsuperscript{b} Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France

ARTICLE INFO

Keywords:
2019-nCoV
SARS-CoV-2
COVID-19
Hydroxychloroquine
Azithromycin
Vero E6

ABSTRACT

Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.

1. Introduction

Since the end of 2019, the world has encountered pandemic conditions attributable to a novel Coronavirus SARS-CoV 2 \cite{1–3}. This is the 7th Coronavirus identified to infect the human population \cite{1,4,5} and the first one that had pandemic potential in non-immune populations in the 21st century \cite{6}. Finding therapeutics is thus crucial, and it is proposed to do so by repurposing existing drugs \cite{7–9}. This strategy presents the advantages that safety profiles of such drugs are known and that they could be easily produced at relatively low cost, thus being quicker to deploy than new drugs or a vaccine. Chloroquine, a decades-old antimalarial agent, an analog of quinine, was known to inhibit the acidification of intracellular compartments \cite{10} and has shown in vitro and in vivo (mice models) activity against different subtypes of Coronavirus: SARS-CoV-1, MERS-CoV, HCoV-229E and HCoV-OC43 \cite{11–16}. In 2004 it was tested in vitro against SARS-CoV \cite{17} and caused a 99\% reduction of viral replication after 3 days at 16 μM. Moreover, tests in vitro have shown inhibition of viral replication on SARS-CoV 2 detected by PCR and by CCK-8 assay \cite{18}. Hydroxychloroquine (hydroxychloroquine sulfate; 7-Chloro-4-[4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline sulfate) has shown activity against SARS-CoV2 in vitro and exhibited a less toxic profile \cite{19}. This drug is well known and currently used mostly to treat autoimmune diseases and also by our team to treat Q fever disease \cite{20,21} and Whipple’s disease \cite{22,23}. In those clinical contexts, concentrations obtained in serum are close to 0.4–1 μg/mL at the dose of 600 mg per day over several months \cite{24}. Clinical tests of chloroquine and hydroxychloroquine to treat COVID-19 are underway in China \cite{25}, with such trials using hydroxychloroquine in progress in the US (ClinicalTrials.gov Identifier: NCT04307693) and in Europe with the Discovery Trial. In this drug repurposing effort, antibacterial components have also been tested. Teicoplanin, a glycopeptide, was demonstrated in vitro to inhibit cellular penetration of Ebola virus \cite{26} and SARS-CoV-2 \cite{26,27}. Azithromycin (azithromycin dihydrate), a macrolide, N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A, has shown antiviral activity against Zika \cite{28–30}. Azithromycin is a well-known and safe drug, widely prescribed in the US, for example, with 12 million treatment courses in children under 19 years of age alone \cite{31}. A recent study has identified these two compounds (azithromycin and hydroxychloroquine) among 97 total potentially active agents as possible treatments for this disease \cite{32}.

In a preliminary clinical study, hydroxychloroquine and, with even greater potency, the combination of hydroxychloroquine and azithromycin were found effective in reducing the SARS-CoV-2 viral load in COVID-19 patients \cite{33}. Since the beginning of the epidemic in the Marseille region we isolated numerous strains and we tested one of them, the SARS-CoV-2 IHUMI-3, using different concentrations of hydroxychloroquine and azithromycin in combination, with Vero E6 cells.

∗ Corresponding author. IHU-Méditerranée Infection, Marseille, France.
∗∗ Corresponding author. IHU-Méditerranée Infection, Marseille, France.
E-mail addresses: bernard.la-scola@univ-amu.fr (B. La Scola), didier.raoult@gmail.com (D. Raoult).

https://doi.org/10.1016/j.micpath.2020.104228

Received 4 April 2020; Received in revised form 17 April 2020; Accepted 22 April 2020
Available online 25 April 2020
0882-4010/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
2. Materials and methods

2.1. Viral isolation procedure and viral stock

The procedure of viral isolation of our SARS-Cov 2 strain IHUMI-3 was detailed elsewhere [33]. The viral production was done in 75 cm² cell culture flask containing Vero E6 cells (American type culture collection ATCC® CRL-1586™) in Minimum Essential Media (Gibco, ThermoFischer) (MEM) with 4% of fetal bovine serum and 1% glutamine. Cytopathic effect was monitored daily over a dissection microscope (Fig. 1). After nearly complete cell lysis (approximately 96 h), viral supernatant was used for inoculation on 96-well plate. We determined the TCID50 of the strain at 5.10⁵ infectious particles per mL.

2.2. Testing procedure for drugs

Briefly, we prepared 96-well plates with 5.10⁵ cells/mL of Vero E6 (200 μL per well), using MEM with 4% of fetal bovine serum and 1% l-glutamine. Plates were incubated overnight at 37 °C in a CO₂ atmosphere. Drug concentrations tested, expressed in micromoles per liter (μM), were 1, 2 or 5 μM for hydroxychloroquine associated with 5 or 10 μM for azithromycin. Each test was done at least in triplicate and repeated two times except conditions with 5 μM for hydroxychloroquine associated with 5 or 10 μM for azithromycin that were repeated a third time. Four hours before infection, cell culture supernatant was removed and replaced by drugs diluted in the culture medium. At t = 0, virus suspension in culture medium was added to all wells except in negative controls where 50 μL of the medium was added. Multiplicity of infection (MOI) was of 0.25. Then RT-PCR was done 30 min post-infection in one plate and again at 60 h post-infection on a second plate. For this, 100 μL from each well was collected and added to 100 μL of the ready-use VXL buffer from QIAcube kit (Qiagen, Germany). The extraction was done using the manual High Pure RNA Isolation Kit (Roche Life Science), following the recommended procedures. The RT-PCR was done using the Roche RealTime PCR Ready RNA Virus Master Kit. The primers were designed against the E gene using the protocol of Amrane el al. [34] in the Roche LightCycler® 480 Instrument II. Relative viral quantification was done compare to the positive control (viruses without drugs) by the 2⁻ΔΔCT method [35]. We performed a statistical analysis using GraphPad Prism v9.0.0 (GraphPad Software, La Jolla California USA). Distribution of the data not followed a normal law. So, non parametric Kruskal-Wallis test was used to compare each combinations against positive controls using ΔCt between H0 and H60. Then, Dunn’s test was used to correct the multiple comparison. All test was used at p = 0.05 parameter and were bilateral (two-sides) and significant P-value was indicated on the data not followed a normal law. So, non parametric Kruskal-Wallis test was used to compare each combinations against positive controls

3. Results

No cytotoxicity was associated with drugs in combination in all 13 control wells (without viruses). We detected RNA viral production from 25 to 16 cycle-thresholds (Ct, inversely correlated with RNA copy numbers) for the positive control that was associated with cell lyses. In all cases, cell lyses at 60 h was correlated with viral production as compared to control (Fig. 1). Combination of azithromycin and hydroxychloroquine led to significant inhibition of viral replication for wells containing hydroxychloroquine at 5 μM in combination with azithromycin at 10 and 5 μM (P-values at 0,0003 for A10H5 and at 0,0004 for A5H5) (Fig. 2A) with relative viral inhibition of 97.5% and 99.1% respectively (Fig. 2B). Others conditions were not significant. In agreement with the relative viral RNA load reduction, a cytopathic effect could be observed in 5/31 wells at 60 h post infection as compared to 13/13 in positive controls.

4. Discussion

In the work we identified a strong synergistic effect of the combination of hydroxychloroquine and azithromycin. Hydroxychloroquine has been demonstrated in vitro to inhibit replication of SARS-CoV1 and 2 [17,19]. Concentrations of drugs for our study were based on the known cytotoxicity of the drugs (50% of cytotoxicity, CC 50) and their effect on microorganisms (50% inhibitory concentration, IC50). With Zika virus, azithromycin showed activity with an IC50 range from 2.1 to 5.1 μM depending on MOI [28] without notable effect on EC 50 at high concentration [29]. The observation of efficacy of azithromycin on RNA viruses is probably shared by some other macrolides. Clarithromycin or the non antibiotic macrolide EM900 were observed as effective on rhinovirus in vitro [36,37]. In vivo sulfate of hydroxychloroquine could be imply in the modulation of the immune response by reducing pro-inflammatory cytokines and by modification of the lysosome acidification procedure [38]. Those aspects may play a key-stone role in severe cases of SARS-coronaviruses. Indeed, in mouse models from SARS-CoV pneumonia and lung affections was associated with cytokines storm [39]. In parallel azithromycin was known as inhibit the viral replication of Zika virus in vitro [29]. And in enlarge viral infection context, azithromycin was associated to up-regulate interferons I and III [30]. Concerning the respiratory syncytial virus, it was also shown that Macrolides reduce the acidity of the lysosome and by the down-regulation of the ICAM-1 protein (36). So, in the SARS-CoV 2 context, azithromycin could potentialize the effect of hydroxychloroquine by similar mechanism.

![Fig. 1. Observations of infected cells resistant or not to viral replication after inoculation of SARS-CoV 2 strain IHUMI-3 at MOI 0.25.](image-url)
On Vero E6 it was shown that for hydroxychloroquine, CC 50 is close to 250 μM (249.50 μM), which is significantly above the concentrations we tested herein [19]. Against SARS-CoV 2, the IC 50 of hydroxychloroquine was determined to be 4.51, 4.06, 17.31, and 12.96 μM with various MOI of 0.01, 0.02, 0.2, and 0.8, respectively.

One of the main criticisms of previously published data was that drug concentrations for viral inhibition used in vitro are difficult to translate clinically due to side effects that would occur at those concentrations. The synergy between hydroxychloroquine and azithromycin that we observed herein is at concentrations achieved in vivo and detected in serum [35] and pulmonary tissues (36–37) respectively. Our data are thus in agreement with the clinical efficacy of the combination of hydroxychloroquine and azithromycin observed by Gautret et al. [33]. They support the clinical use of this drug combination, especially at the early stage of the COVID-19 infection before the patients develop respiratory distress syndrome with associated cytokine storm and become less treatable by any antiviral treatment.

Funding

This research was funded by the French Government under the “Investissements d’avenir” (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, French National Agency for Research), (reference: Mediterranean Infection 10-IAHU-03), by Région Provence-Alpes-Côte d’Azur and European funding FEDER PRIMI.

Author statement

Virus culture and drug testing: JA, ML, ID, NW; Molecular biology testing: PJ, CR, MB; Analyzed the results: JA, JMR, PC, BL, DR; Wrote the manuscript: JA, BL; Conceived the study: BL, DR.

Pictures were captured on ZEISS AxioCam ERC 5s, 58 h post infection. Magnitude X200.3A-B-C. overview of the monolayer in each well for the condition of azithromycin 5 μM associated with hydroxychloroquine at 5 μM, 3D. Negative control well and 3E. Positive control well. 1F. Observation was done 48 h post infection by the SARS-CoV-2 strain IHUMI-3 for the viral stock production. Magnitude X400.

Declaration of competing interest

Authors would like to declare that Didier Raoult is a consultant in microbiology for Hitachi High-Tech Corporation. Funding sources had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The others authors declare no conflict of interest.

Acknowledgments

The authors are indebted to David Scheim for background literature searching and editing the English version of this paper and Matthieu Million for statistical analysis.

References

[1] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (8) (2020 Feb 20) 727–733.
[2] W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. (2020 Feb 28), https://doi.org/10.1056/NEJMoa2002032 Epub ahead of print.
[3] C. Rothe, M. Schunk, P. Sothmann, G. Bretzel, G. Frosch, C. Wallrauch, et al., Transmission of 2019-nCoV infection from an asymptomatic contact in Germany, N. Engl. J. Med. 382 (10) (2020 Mar 5) 970–971.
[4] A.M. Zaki, B.S. van, T.M. Bestebroer, A.D. Osterhaus, R.A. Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med. 367 (19) (2012 Nov 8) 1814–1820.
[5] A. Vabret, J. Dina, S. Gourarin, J. Petitjean, V. Tripey, J. Brouard, et al., Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France, J. Paediatr. Child Health 44 (4) (2008 Apr) 176–181.
[6] D.M. Morens, G.K. Folkers, A.S. Fauci, What is a pandemic? J. Infect. Dis. 200 (7) (2009 Oct 1) 1018–1021.
[7] R.L. Kruse, Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China, F1000Res 9 (2020) 72.
[8] C.C. Lai, T.P. Shih, W.C. Ko, H.J. Tang, P.R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int. J. Antimicrob. Agents 55 (3) (2020 Mar) 105924.
[9] P. Colson, J.M. Rolain, J.C. Lagier, P. Brouqui, D. Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int. J. Antimicrob. Agents (2020 Mar 4) 105932.
[10] S. Ohkuma, B. Poole, Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH various agents, Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 3327–3331.
[11] E. Keyaerts, S. Li, L. Vigjen, E. Eysman, J. Verbeeck, R.M. Van, et al., Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice, Antimicrob. Agents Chemother. 53 (8) (2009 Aug) 3416–3421.
[12] M.J. Vincent, E. Bergeron, S. Benjannet, B.R. Erickson, P.E. Rollin, T.G. Ksiazek, et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J. 2 (2005 Aug 22) 69.
[13] A. Savarino, J.R. Boelaert, A. Cassone, G. Majori, R. Cauda, Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect. Dis. 3 (11) (2003 Nov) 722–727.
[14] A.H. de Wilde, D. Jochmans, C.C. Posthuma, J.C. Zevenhoven-Dobbe, N.S. van, T.M. Bestebroer, et al., Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother. 58 (8) (2014 Aug) 4875–4884.
